GATA3 and neoplasm: Taking advantage of Gata3 and Brca1 deficient tumor cells lacking Gata3 and expressing high level of Fra1 [15, 38, 39] (Fig. 5E), we knocked out Fra1 in these cells by using the CRISPR/Cas9 system (Fig. 5F, I).